{"nctId":"NCT00059839","briefTitle":"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma","startDateStruct":{"date":"2003-11"},"conditions":["Lymphoma"],"count":129,"armGroups":[{"label":"Standard APO with Vincristine (Arm I )","type":"EXPERIMENTAL","interventionNames":["Drug: doxorubicin hydrochloride","Drug: mercaptopurine","Drug: methotrexate","Drug: prednisone","Drug: vincristine sulfate"]},{"label":"Consolidation with Vinblastine","type":"EXPERIMENTAL","interventionNames":["Drug: doxorubicin hydrochloride","Drug: mercaptopurine","Drug: methotrexate","Drug: prednisone","Drug: vinblastine sulfate"]}],"interventions":[{"name":"doxorubicin hydrochloride","otherNames":[]},{"name":"mercaptopurine","otherNames":[]},{"name":"methotrexate","otherNames":[]},{"name":"prednisone","otherNames":[]},{"name":"vinblastine sulfate","otherNames":[]},{"name":"vincristine sulfate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Newly diagnosed advanced anaplastic large cell lymphoma\n\n  * Cluster of differentiation antigen 30 (CD30+)\n  * Murphy stage III or IV\n* No B-cell large cell lymphoma\n* No disease limited to the skin (regardless of how wide-spread)\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* Under 21\n\nPerformance status\n\n* Not specified\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) or alanine transaminase (ALT) less than 2.5 times ULN (unless due to lymphoma)\n\nRenal\n\n* Not specified\n\nCardiovascular\n\n* Shortening fraction (SF) at least 27% by echocardiogram OR\n* Ejection fraction (EF) at least 50% by radionuclide angiogram\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* Not specified\n\nEndocrine therapy\n\n* Prior steroids for management of a mediastinal mass allowed\n\nRadiotherapy\n\n* Prior limited-dose radiotherapy for a mediastinal mass allowed\n\nSurgery\n\n* Not specified","healthyVolunteers":false,"sex":"ALL","maximumAge":"20 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-free Survival (EFS)","description":"Percentage of EFS patients. This is measured as the time from study entry until disease progression, disease recurrence, occurrence of a second malignant neoplasm, or death from any cause. To measure Event Free Survival, repeated one-sided logrank tests will be performed The upper critical values are based on the one-sided alpha-spending functions of t2 (alpha=0.05) and the lower critical values are based on testing the alternative hypothesis at 0.005 level.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":64},"commonTop":["Neutrophil count decreased","White blood cell decreased","Alanine aminotransferase increased","Anemia","\"Infections and infestations - Other\""]}}}